RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The present study investigated the role of peripheral cannabinoid (CB2) receptors in producing hypomobility, antinociception and hypothermia in mice. Results revealed that the CB2-selective antagonist, SR144528, did not block cannabimimetic effects of a potent Delta(8)-tetrahydro-cannabinol (THC) analog in mice. While most of a series of CB2-selective 1-deoxy-THC analogs were active in vivo only if they also had good affinity for CB1 receptors, four of these analogs showed in vivo activity even though their affinities for CB1 receptors were poor. Further, this activity was blocked by the CB1 antagonist SR141716A, but not by SR144528. One of the deoxy analogs also stimulated [S-35]GTPgammaS binding, an effect that was blocked by SR141716A. These results provide further evidence that these cannabimimetic effects are not mediated through action at CB2 receptors. In addition, some of these analogs may be very low efficacy agonists at CB1 receptors that act as full agonists in vivo, but lack the ability to displace high affinity and high efficacy binding ligands in vitro. Copyright (C) 2002 S. Karger AG, Basel